[Previous Months][Date Index][Thread Index][Join - Register][Login]
[Message Prev][Message Next][Thread Prev][Thread Next]

[IP] Fwd: Cygnus Launches GlucoWatch® Biographer in U.S.

Date: Mon, 15 Apr 2002 08:37:12 -0400

This News Release will be posted on Cygnus' website at 
http://www.cygn.com/press/news.html as soon as possible after it is released 
to the media.

Please note: This email service is intended solely to distribute 
information, and is not designed to be an interactive email system. Please 
note that replies to Cygnus' email announcement will not be responded to. 
For additional information, please contact Cygnus by phone at (650) 
369-4300, fax at (650) 599-2503 or visit our homepage at: www.cygn.com.

Cygnus Launches GlucoWatch(R) Biographer in U.S.
The only FDA-approved product that provides
frequent, automatic and non-invasive measurement of glucose levels

Redwood City, CA - April 15, 2002 - Cygnus, Inc. (Nasdaq: CYGN) today 
announced the U.S. market launch of the GlucoWatch(R) Biographer, the only 
product approved by the U.S. Food and Drug Administration (FDA) for 
consumers designed to measure glucose levels frequently, automatically and 
non-invasively.  The frequent and automatic measurements provided by the 
GlucoWatch Biographer can identify trends and track patterns in fluctuating 
glucose levels that would be difficult for people with diabetes and their 
health care teams to detect with current testing techniques alone.

"We are very excited about making the GlucoWatch Biographer available in the 
United States.  It represents the most significant technological 
breakthrough in glucose monitoring since the transition from urine dip 
sticks to blood meters about twenty years ago.  Numerous clinical studies 
have demonstrated the health benefits of frequent glucose testing and more 
frequent insulin injections.  Unfortunately, the vast majority of people 
with diabetes do not test their glucose levels frequently enough and 
fluctuating glucose levels make it extremely difficult for detection with 
current testing methods alone," stated John C Hodgman, Chairman, Chief 
Executive Officer and President of Cygnus, Inc.  "There is an unmet need for 
a product that can readily provide frequent glucose measurements.  The 
GlucoWatch Biographer can be the solution for millions of people with 

The GlucoWatch Biographer is the first and only glucose monitoring system 
that provides readings frequently, automatically and non-invasively, up to 
three times an hour, for up to twelve hours day or night.  The Biographer is 
a glucose monitoring device designed to detect trends and track patterns in 
glucose levels in adults (ages 18 and older) with diabetes.  This device is 
intended for use by patients at home and in health care facilities.  It is 
for prescription use only.  The Biographer is intended for use an adjunctive 
device to supplement, not replace, information obtained from standard home 
glucose monitoring devices.  The GlucoWatch Biographer is indicated for use 
in detection and assessment of episodes of hyperglycemia and hypoglycemia, 
facilitating both acute and long-term therapy adjustments, which may 
minimize these excursions. Interpretation of Biographer results should be 
based on the trends and patterns seen within several sequential readings 
over time.

The GlucoWatch Biographer differs from other glucose monitoring systems in 
several ways.  It is non-invasive, collecting glucose through the skin, not 
from blood.  It automatically measures and displays glucose levels and 
detects trends and patterns in glucose levels as opposed to a single, 
discrete reading.  It has alert systems to inform users when glucose levels 
are too high, too low or declining rapidly.  The Biographer also stores up 
to 4,000 glucose values in an electronic diary that can be reviewed at the 
touch of a button or uploaded into a software program to enable detailed 
analysis of glucose fluctuations.

"The GlucoWatch Biographer represents a tremendous advance in diabetes 
management," said Steven Edelman, M.D., Professor of Medicine, Division of 
Diabetes and Metabolism, University of California San Diego School of 
Medicine and Veterans Affairs, and the founder and Director of the 
non-profit organization Taking Control of Your DiabetesTM.  "Most people 
with diabetes are not fully aware of the frequent fluctuations they have in 
their glucose levels.  I have many patients who will benefit greatly from 
the insight they will gain from the additional information provided by the 
Biographer," added Dr. Edelman.

The GlucoWatch Biographer will be available for sale through direct mail, 
not through retail pharmacies.  People interested in learning more about the 
GlucoWatch Biographer and how to order can request information by calling 
toll free 1-866-GLWATCH (1-866-459-2824) or by visiting www.glucowatch.com.  
To obtain a GlucoWatch Biographer, adults with diabetes will need to consult 
a health care professional to get a prescription, complete the order form 
contained in the Introductory Training Brochure and complete a questionnaire 
to be sure the device is right for them.

The GlucoWatch Biographer consists of two main parts: the durable 
Biographer, which is the watch-like device that attaches to a person's 
forearm, and the AutoSensor, the disposable component that attaches to the 
back of the Biographer and allows for glucose monitoring for up to 12 hours. 
The price of the Starter Kit, which includes the GlucoWatch Biographer, 
instructional video, user guide, battery charger and two rechargeable 
batteries, as well as other accessories, is $595. AutoSensors are sold in 
cartons of 16 and sell for $69.75.  Also available for sale at $35.00 is the 
GlucoWatch(R) Analyzer, FDA-approved software that downloads data retrieved 
by the individual's Biographer into a personal computer for display and 
storage of data.  The software uses the data to generate statistical reports 
and graphs that are designed to create a comprehensive picture of an 
individual's recent glucose level history and allow for analysis of trends 
and patterns in glucose levels.  Purchases can only be made by using VISA(R) 
or MasterCard(R) credit cards.  At the completion of the transaction, the 
GlucoWatch Biographer and associated products will be shipped directly to 
the consumer.

Cygnus and Sankyo have been collaborating closely on sales and marketing 
efforts under an agreement signed in November 2001. The co-promotion 
agreement covers the GlucoWatch Biographer and other similar glucose 
monitoring products in the United States. The agreement calls for Sankyo to 
provide a 50-person specialty sales force, well-versed in diabetes and its 
treatment, to leverage Sankyo's already established relationships with 
physicians having the highest potential for prescribing the GlucoWatch 
Biographer. Sankyo may also provide broad market coverage through their 450 
primary care sales representatives.  In addition, Sankyo may deploy 20 
managed care account managers to obtain insurance reimbursement for the 
GlucoWatch Biographer and 20 medical managers who would communicate key 
scientific data to medical professionals.

The World Health Organization estimates there are 125 million people 
worldwide with diabetes. This number has increased 15% in the last 10 years 
and is expected to double by 2025. In the United States, approximately 10 
million Americans have been diagnosed with diabetes and each year 
approximately 13,000 children are diagnosed. Diabetes is a leading cause of 
death in the United States, and the complications of uncontrolled diabetes 
result in an estimated $100 billion in medical costs annually. The current 
worldwide market for glucose measuring products is estimated at between $3 
billion and $4 billion, and it is expected to exceed $4.7 billion in 2002. 
The United States is estimated to account for 50%-60% of all sales, while 
Western Europe accounts for approximately 30% of sales.

Cygnus, Inc. is engaged in the development and manufacture of diagnostic 
medical devices, utilizing proprietary technologies to satisfy unmet medical 
needs cost-effectively. The first such device is a frequent, automatic and 
non-invasive glucose monitoring device, the first-generation GlucoWatch 
Biographer. A supplemental pre-market approval (PMA) submission is currently 
under expedited review by the FDA for use of the GlucoWatch Biographer by 
children and adolescents (ages 7-17). The GlucoWatch Biographer has also 
received the CE mark permitting sales in the European Union, and Cygnus is 
currently selling the first-generation product in the United Kingdom.

Sankyo Pharma Inc. is a wholly owned subsidiary of Sankyo Co. Ltd., the 
second largest drug company in Japan.  Sankyo is a recognized research-based 
company and a source of new therapeutic agents, including drugs for 
cardiovascular disease and diabetes.

More information about Cygnus can be found at the corporate web site: 
http://www.cygn.com. Additional information about the GlucoWatch Biographer 
can be obtained by calling the Company's toll-free number, 1-866-GLWATCH, or 
by visiting http://www.glucowatch.com.

Some of the statements in this news release are forward-looking statements 
that involve risks and uncertainties. These forward-looking statements 
include statements about the Company's plans, objectives, expectations, 
intentions and assumptions and other statements contained in this news 
release that are not statements of historical fact. Forward-looking 
statements include, but are not limited to, statements about the Company's 
ability to manufacture and scale-up commercially the GlucoWatch Biographer, 
the Company's plans for commercialization alliances, the Company's ability 
to achieve market acceptance of the GlucoWatch Biographer, and the Company's 
plans for enhancements and possible manufacturing changes through the 
regulatory process. In some cases, you can identify these statements by 
words such as "may," "will," "should," "estimates," "predicts," "potential," 
"continues," "strategy," "believes," "anticipates," "plans," "expects," 
"intends" and similar expressions. Cygnus cannot guarantee future results, 
levels of activity, performance or achievements. Actual results and the 
timing of certain events may differ significantly from the results discussed 
in the forward-looking statements. The Company refers you to the documents 
the Company files from time to time with the Securities and Exchange 
Commission, including the Company's Annual Report on Form 10-K, Quarterly 
Reports on Form 10-Q and Current Reports on Form 8-K, which contain 
descriptions of certain factors that could cause the Company's actual 
results to differ from the Company's current expectations and any 
forward-looking statements contained in this news release. "GlucoWatch" is a 
registered trademark of Cygnus, Inc.

Get your FREE download of MSN Explorer at http://explorer.msn.com/intl.asp.
for HELP or to subscribe/unsubscribe, contact: HELP@insulin-pumpers.org
send a DONATION http://www.Insulin-Pumpers.org/donate.shtml